Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.60
ATEC's Cash-to-Debt is ranked higher than
65% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ATEC: 0.60 )
Ranked among companies with meaningful Cash-to-Debt only.
ATEC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.63 Max: N/A
Current: 0.6
Equity-to-Asset -0.31
ATEC's Equity-to-Asset is ranked lower than
96% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ATEC: -0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
ATEC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.44  Med: 0.55 Max: 0.72
Current: -0.31
-0.44
0.72
Piotroski F-Score: 4
Altman Z-Score: -5.88
Beneish M-Score: -3.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -12.88
ATEC's Operating Margin % is ranked lower than
69% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. ATEC: -12.88 )
Ranked among companies with meaningful Operating Margin % only.
ATEC' s Operating Margin % Range Over the Past 10 Years
Min: -130.86  Med: -12.6 Max: 0.96
Current: -12.88
-130.86
0.96
Net Margin % -22.95
ATEC's Net Margin % is ranked lower than
74% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. ATEC: -22.95 )
Ranked among companies with meaningful Net Margin % only.
ATEC' s Net Margin % Range Over the Past 10 Years
Min: -132.96  Med: -18.06 Max: -7.88
Current: -22.95
-132.96
-7.88
ROA % -25.48
ATEC's ROA % is ranked lower than
75% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. ATEC: -25.48 )
Ranked among companies with meaningful ROA % only.
ATEC' s ROA % Range Over the Past 10 Years
Min: -72.74  Med: -11.49 Max: -3.63
Current: -25.48
-72.74
-3.63
ROC (Joel Greenblatt) % -63.17
ATEC's ROC (Joel Greenblatt) % is ranked lower than
70% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. ATEC: -63.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATEC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -259.32  Med: -40.15 Max: 6.08
Current: -63.17
-259.32
6.08
3-Year Revenue Growth Rate -18.10
ATEC's 3-Year Revenue Growth Rate is ranked lower than
75% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ATEC: -18.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATEC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: -0.9 Max: 32.4
Current: -18.1
-18.1
32.4
3-Year EBITDA Growth Rate -36.80
ATEC's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ATEC: -36.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATEC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.9 Max: 96.2
Current: -36.8
0
96.2
3-Year EPS without NRI Growth Rate -33.10
ATEC's 3-Year EPS without NRI Growth Rate is ranked higher than
96% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ATEC: -33.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ATEC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.1  Med: -16.7 Max: 128.2
Current: -33.1
-52.1
128.2
GuruFocus has detected 2 Warning Signs with Alphatec Holdings Inc $ATEC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATEC's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ATEC Guru Trades in Q2 2016

Jim Simons 1,045,800 sh (+17.64%)
» More
Q3 2016

ATEC Guru Trades in Q3 2016

Jim Simons 169,245 sh (+94.20%)
» More
Q4 2016

ATEC Guru Trades in Q4 2016

Jim Simons 313,545 sh (+85.26%)
» More
Q1 2017

ATEC Guru Trades in Q1 2017

Jim Simons 300,987 sh (-4.01%)
» More
» Details

Insider Trades

Latest Guru Trades with ATEC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:BMRA, NAS:PDEX, OTCPK:LDSYF, AMEX:DXR, NAS:CASM, NAS:BLFS, OTCPK:REPR, AMEX:INFU, OTCBB:NEPH, OTCPK:STXS, NAS:AKER, AMEX:ISR, OTCPK:IGAP, NAS:VLRX, NAS:SKLN, OTCPK:UEEC, AMEX:RVP, OTCPK:VPTDF, NAS:SSKN, OTCPK:REMI » details
Traded in other countries:L1Z1.Germany,
Headquarter Location:USA
Alphatec Holdings Inc is a medical technology company. It is engaged in the design, development and promotion of products for the surgical treatment of spine disorders.

Alphatec Holdings Inc was incorporated on March 4, 2005. The Company is a medical technology company, which is engaged in the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a focus on products that treat conditions that affect the aging spine. The Company's product portfolio and pipeline includes a number of spinal disorder products and systems focused on solutions addressing the cervical, thoracolumbar, intervertebral, minimally invasive, vertebral compression fracture, osteoporotic bone, and spinal stenosis markets. Its main product offerings are focused on the market for orthopedic spinal disorder solution products. The Company also sells allograft spacers available in different shapes and sizes, each with corresponding instrumentation, which are intended for use in the cervical, thoracic, and lumbar regions of the spine. The Company operates an in-house manufacturing facility that enables it to deliver solutions to meet surgeons' and patients' needs. In addition to selling its products in the U.S., the Company also sells its products in Japan, the European Union and Hong Kong. It conducts its manufacturing operations at its facilities in Carlsbad, California. Its products and systems are made of titanium, titanium alloy, stainless steel and a strong, heat resistant, radiolucent, biocompatible plastic called polyetheretherketone, or PEEK. It sells its products directly to distributors, and its distributors resell its products to hospitals. The competitors of Company are Medtronic Sofamor Danek, Johnson & Johnson (DePuy/Synthes), Stryker, Biomet, NuVasive, Zimmer, Orthofix, Globus Medical, Integra Life Science, LDR Spine and others. The Company's products are subject to extensive regulation by the FDA and other U.S. federal and state regulatory bodies and comparable authorities in other countries.

Top Ranked Articles about Alphatec Holdings Inc

Alphatec Holdings to Report First Quarter 2017 Financial Results on May 11, 2017
Alphatec Spine Launches Battalion™ Lateral System with Squadron™ Retractor to support Minimally Invasive Lateral Access Procedures
Alphatec Spine Adds Experienced Spine Executives to Sales Leadership Team
Alphatec Completes its Senior Leadership Team with Appointment of Brian Snider, Executive Vice President, Strategic Marketing and Product Development

Chris Ryan Named Area Vice President of Sales, U.S. Central region
New leaders add significant spine-industry experience to build brand awareness and drive market adoption of Alphatec products
CARLSBAD, Calif., March 24, 2017 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (NASDAQ:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced today the addition of two new executives with proven track records in the spine industry, naming Brian Snider as Executive Vice President, Strategic Marketing and Product Development, and Chris Ryan as Area Vice President of Sales in the U.S. Central Region.  Drawing on their deep commercial spine experience, Mr. Snider and Mr. Ryan will focus on building brand awareness with surgeon customers and driving market demand for Alphatec’s differentiated product solutions.  Brian Snider Named EVP Strategic Marketing and Product Development “I am pleased to welcome Brian to the Alphatec Senior Leadership Team,” said Terry Rich, Alphatec Spine’s Chief Executive Officer.  “Brian’s arrival completes our efforts over the past few months to restructure Alphatec leadership by adding individuals with significant spine and orthopedic experience. Brian brings an unquestioned track record of building strong surgeon relationships, product innovation, and commercialization, having brought to market over 30 innovative spine products and procedures.  We look forward to leveraging his energy and expertise, as we launch our new products, including Battalion™ Lateral and Arsenal™ Deformity, deepen our engagement with surgeons, and aggressively build our brand.  I look forward to partnering with Brian and believe his contributions will help take Alphatec to the next level of innovation and growth.” As Alphatec’s Executive Vice President, Strategic Marketing and Product Development, Mr. Snider will lead all aspects of the Company’s go-to-market strategy, including product development, marketing, brand awareness and driving market adoption. Mr. Snider has spent the past 11 years focused on marketing, brand and product development, and global product management in the spine and medical device industries.  Prior to joining Alphatec Spine, Mr. Snider spent nine years at NuVasive, Inc., where he most recently served as the Business Lead of Thoracolumbar Anterior, and had substantial responsibility over the anterior column business, including XLIF® and Anterior Column Realignment (ACR®).  Prior to NuVasive, Mr. Snider held marketing leadership roles at Alveolus, Inc., a medical device company focused on interventional stent technologies.  He started his career at KPMG consulting in various business units, including Life Sciences. Mr. Snider holds an MBA from the Fuqua School of Business at Duke University and a Bachelor’s degree in Business Administration from The George Washington University.  Chris Ryan Named AVP Sales, Central Region “I’m excited to bring Chris onboard as the first of our new regional area sales vice presidents,” said Mr. Rich.  “Given the recent launch of our three new products— Arsenal Deformity, Battalion Lateral and XYcor® Expandable Interbody—this is a perfect time for Chris to join the Alphatec team.  Chris brings a combination of high-performing sales leadership and distribution channel transformation experience that will be crucial to leading our sales agent relationships and accelerating our growth.  His reputation for high integrity, his deep understanding of the spine industry and his proven ability to drive significant revenue will make him an asset to our organization.” As Alphatec’s Area Vice President, Sales, Central, Mr. Ryan will be responsible for expanding the Company’s presence in the Central United States, including building dedicated sales agent relationships, targeting new customer and market opportunities, as well as providing service and support for existing surgeon customers.   Mr. Ryan brings more than 20 years of progressive spine sales leadership experience to Alphatec.  Prior to joining Alphatec, Mr. Ryan held multiple sales leadership roles over a six-year period with Zimmer Biomet Spine, including as its Vice President of U.S. Sales and a member of the Zimmer Spine Leadership Team. Under Mr. Ryan's leadership, Zimmer’s U.S. Spine Sales channel underwent a substantial, strategic change in distribution, yielding significant annual revenue growth.  Prior to Zimmer, Mr. Ryan served in a number of leadership capacities during his 14-year career at Medtronic, including Regional Vice President of Medtronic Spinal and Biologics business unit, responsible for Medtronic’s Central Region.   Mr. Ryan holds a Bachelor of Science in Economics from Western Michigan University.  Inducement Awards Granted As an inducement to entering into employment with the Company and in accordance with NASDAQ Listing Rule 5635(c)(4) under Alphatec’s 2016 Employment Inducement Award Plan (the “Plan”), on March 16, 2017, the Compensation Committee of the Board of Directors approved the following inducement awards: Mr. Snider: 75,000 restricted stock units (RSUs) (with the grant of such RSUs made subject to, and effective on, the date on which Alphatec files a Registration Statement on Form S-8 registering the shares of common stock issuable upon settlement of the RSUs, which filing is expected to occur later this month) and an option to purchase 75,000 shares of common stock.

Mr. Ryan: 25,000 restricted stock units (RSUs) (with the grant of such RSUs made subject to, and effective on, the date on which Alphatec files a Registration Statement on Form S-8 registering the shares of common stock issuable upon settlement of the RSUs, which filing is expected to occur later this month) and an option to purchase 25,000 shares of common stock.
The RSUs and stock options were granted pursuant to the Plan.  Collectively, the RSUs and options were granted as inducements material to the new employees entering into employment with Alphatec in accordance with NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments annually over four years on each of the first four anniversaries of the first date of employment, assuming in each case the employee remains continuously employed by Alphatec as of such vesting date. In addition, the RSUs will fully vest upon a change in control of Alphatec. The stock options will have an exercise price equal to the closing price per share of Alphatec’s common stock as reported by NASDAQ on the date of grant (March 20, 2017). The stock options will vest over four years, with 25% of the options vesting on the first anniversary of the date of grant and the remainder of the options vesting monthly over the subsequent three years, assuming in each case the employee remains continuously employed by Alphatec as of such vesting date. In addition, the options will fully vest upon a change in control of Alphatec. Alphatec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4). About Alphatec Spine Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company markets products in the U.S. via independent sales agents and a direct sales force. Additional information can be found at www.alphatecspine.com.  Forward Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.  Forward-looking statements include the Company's ability to launch new products, deepen surgeon engagement, build brand awareness and accelerate growth. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to:  the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainty of success in launching new products and developing new products or products currently in the Company’s pipeline; the failure to achieve acceptance of the Company’s products by the surgeon community; continuation of favorable third party payor reimbursement for procedures performed using the Company's products; the Company's ability to compete with other competing products and with emerging new technologies; and the Company's ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement.  Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K.  Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. 
CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610 
[email protected]

Read more...
Alphatec Holdings Announces $18.9 Million Private Placement

Proceeds to support corporate growth strategy

CARLSBAD, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (NASDAQ:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced today that it has entered into a definitive securities purchase agreement to raise approximately $18.9 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock. The private placement is being led by new healthcare dedicated institutional investors, with participation by directors and executive officers of Alphatec and other existing investors. The private placement is expected to close on or about March 28, 2017, subject to the satisfaction of customary closing conditions. Alphatec expects to use the net proceeds from the private placement for general corporate and working capital purposes.
“We appreciate the support of our new and existing investors and the confidence this conveys in our strategy to build a high-growth spine company,” said Terry Rich, Alphatec Spine’s Chief Executive Officer.  “We believe the additional capital will allow us to execute on our plans to expand our surgeon customer base, drive growth through the launch of our new products—Arsenal Deformity™, Battalion™ Lateral and XYcor® Expandable Interbody—as well as support the transformation of our distribution channel.” H.C. Wainwright & Co., LLC, is acting as the exclusive placement agent in connection with this private placement. Pursuant to the terms of the securities purchase agreement, Alphatec has agreed to sell 1,809,628 shares of common stock at a price of $2.00 per share.  In addition, Alphatec has agreed to sell approximately 15,245 shares of newly created Series A Convertible Preferred Stock, which shares of preferred stock are convertible into approximately 7,622,372 shares of common stock, subject to limitations on conversion until the approval by Alphatec’s stockholders as required in accordance with the NASDAQ Global Select Market rules. Purchasers will also receive warrants to purchase up to approximately 9,432,000 shares of common stock at an exercise price of $2.00 per share. The warrants will be exercisable following approval by Alphatec stockholders, and will expire 5 years from the date of such stockholder approval. Certain directors and executive officers of Alphatec agreed to purchase an aggregate of $2.35 million of shares of Series A Convertible Preferred Stock, which shares are convertible into approximately 1,175,000 shares of common stock, and warrants to purchase up to 1,175,000 shares of common stock at a price of $2.00 per share. The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. Alphatec has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock purchased in the private placement and the shares of common stock underlying the warrants and issuable upon conversion of the Series A Convertible Preferred Stock. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. About Alphatec Spine Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. via a direct sales force and independent distributors. Additional information can be found at www.alphatecspine.com. Forward Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward looking statements include statements regarding: Alphatec’s expectations on the completion, timing and size of the private placement and the anticipated use of proceeds therefrom, including such proceeds allowing Alphatec to accelerate its plans to expand its surgeon customer base, drive growth through the launch of new products and support the transformation of its distribution channel.  The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, risks and uncertainties associated with: market conditions and the satisfaction of customary closing conditions related to the private placement; the uncertainty of success in launching new products; the uncertainties in Alphatec’s ability to execute upon its strategic operating plan; failure to achieve acceptance of Alphatec Spine's products by the surgeon community; continuation of favorable third-party payor reimbursement for procedures performed using Alphatec Spine's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec’s ability to successfully control its costs or achieve profitability; Alphatec's ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement; and other risks and uncertainties inherent in Alphatec's business, including those detailed from time to time in Alphatec’s SEC reports, including its Annual Report Form 10-K for the year ended December 31, 2015, filed on March 15, 2016 with the Securities and Exchange Commission, and its Amended Annual Report Form 10-K/A filed on April 29, 2016, as well as other filings on Form 10-Q and periodic filings on Form 8-K. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  Alphatec disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
[email protected]

Read more...
Alphatec Spine Appoints Jeffrey G. Black as Chief Financial Officer

Financial executive with extensive public-company experience to help strengthen the Company’s foundation and position for growth
CARLSBAD, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Alphatec Spine, Inc. (NASDAQ:ATEC), a provider of spinal fusion technologies, announced today that it continues its investment in new executive talent with the hiring of Jeffrey G. Black as Executive Vice President and Chief Financial Officer.
Mr. Black is a seasoned executive with over 25 years of experience in financial and operations management, including senior-level finance roles for six publicly-traded companies. As the CFO at Alphatec, Mr. Black will lead the finance, investor relations and accounting organizations, architecting the appropriate capital structure for the Company to execute its strategy and build a sustainable financial foundation for future growth.“Jeff’s financial insight, capital restructuring and financing experience, as well as his open leadership style will be great enhancements to the Alphatec team,” said Terry Rich, Chief Executive Officer of Alphatec Spine.  “His history of successfully leading growing organizations, his Wall Street relationships in the healthcare sector, and his strong discipline in cost and cash control make him an ideal fit for Alphatec.  I look forward to partnering with Jeff as we continue to build a high-growth U.S. spine company and improve surgeons’ experiences and patient outcomes through our differentiated product offerings. We also thank Dennis Nelson, Vice President, Finance, for serving as Alphatec’s Principal Accounting Officer, and offering strong leadership of our finance and accounting organizations while we engaged in the CFO search.”Mr. Black, 48, previously served as the Chief Financial Officer of Applied Proteomics, Inc., a company that develops novel, non-invasive diagnostics using a proteomics-based platform.  Before joining Applied Proteomics, Mr. Black served as the Chief Financial Officer of AltheaDx, Inc., a molecular diagnostics company specializing in pharmacogenetic testing.  Prior to AltheaDx, Mr. Black served as Chief Financial Officer of Verenium Corporation (formerly Diversa Corporation), a Nasdaq-listed pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. During his nine-year tenure at Verenium/Diversa, Mr. Black played a leadership role in more than $500 million of strategic, equity, and debt financing transactions, culminating in the sale of the company to BASF in 2013. Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP. He currently serves on the Board of Directors of Cellana, Inc., a privately-held algae bioproducts company.“I am pleased to be joining Terry and his high-caliber leadership team, with a proven record of success in the spine market,” said Mr. Black.  “With this new team in place, a robust product portfolio, and a rich pipeline of new products, Alphatec is well-positioned to continue on an accelerated path to improve patient lives.  I am excited to be a part of the company’s transformation, with an eye toward building value for shareholders.”As an inducement to entering into employment with the Company and in accordance with NASDAQ Listing Rule 5635(c)(4) under Alphatec’s 2016 Employment Inducement Award Plan (the “Plan”), on February 21, 2017, the Compensation Committee of the Board of Directors approved the following inducement awards to Mr. Black: 75,000 restricted stock units (RSUs) (with the grant of such RSUs made subject to, and effective on, the date on which Alphatec files a Registration Statement on Form S-8 registering the shares of common stock issuable upon settlement of the RSUs, which filing is expected to occur later this month) and an option to purchase 75,000 shares of common stock.The RSUs and stock options were granted pursuant to the Plan.  Collectively, the RSUs and options were granted as inducements material to Mr. Black entering into employment with Alphatec in accordance with NASDAQ Listing Rule 5635(c)(4).The RSUs will vest in equal installments annually over four years on each of the first four anniversaries of Mr. Black’s first date of employment, assuming in each case that he remains continuously employed by Alphatec as of such vesting date. In addition, the RSUs will fully vest upon a change in control of Alphatec.The stock options will have an exercise price equal to the closing price per share of Alphatec’s common stock as reported by NASDAQ on the date of grant (March 6, 2017). The stock options will vest over four years, with 25% of the options vesting on the first anniversary of the date of grant and the remainder of the options vesting monthly over the subsequent three years, assuming in each case Mr. Black remains continuously employed by Alphatec as of such vesting date. In addition, the options will fully vest upon a change in control of Alphatec.The Board approved an amendment to the Plan to increase the shares reserved for issuance thereunder by 600,000 shares, effective February 21, 2017.Alphatec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).Further information regarding the Company’s appointment of Jeffrey G. Black as Executive Vice President Finance and Chief Financial Officer is set forth in a Current Report on Form 8-K that was filed with the U.S. Securities and Exchange Commission (SEC) on March 6, 2017 and is available on both the SEC’s website at www.sec.gov and the Company’s website at www.alphatecspine.com.About Alphatec SpineAlphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. via a direct sales force and independent distributors.Additional information can be found at www.alphatecspine.com. Forward Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.  Forward-looking statements include the Company's ability to build a high-growth U.S. spine company; ability to strengthen its position in the U.S. spine market; ability to improve surgeon’s experiences, patient outcomes and patient lives; ability to build value for shareholders;  ability to architect the appropriate capital structure; ability to build a sustainable financial foundation for future growth; the potential of the Company’s pipeline of products; and the Company’s ability to achieve its strategic goals.  The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to:  the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainty of success in developing new products or products currently in the Company’s pipeline; the failure to achieve acceptance of the Company’s products by the surgeon community; the failure to obtain FDA clearance or approval for new products or prolonged delays in the process; continuation of favorable third party payor reimbursement for procedures performed using the Company's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company's ability to compete with other competing products and with emerging new technologies; product liability exposure; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement.  Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K.  Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.13
ATEC's PS Ratio is ranked higher than
98% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ATEC: 0.13 )
Ranked among companies with meaningful PS Ratio only.
ATEC' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.95 Max: 2.86
Current: 0.13
0.12
2.86
EV-to-EBIT -1.43
ATEC's EV-to-EBIT is ranked lower than
99.99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. ATEC: -1.43 )
Ranked among companies with meaningful EV-to-EBIT only.
ATEC' s EV-to-EBIT Range Over the Past 10 Years
Min: -68  Med: -7.1 Max: 62.1
Current: -1.43
-68
62.1
EV-to-EBITDA -2.41
ATEC's EV-to-EBITDA is ranked lower than
99.99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. ATEC: -2.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATEC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1255.7  Med: -3.7 Max: 139.9
Current: -2.41
-1255.7
139.9
Current Ratio 2.17
ATEC's Current Ratio is ranked lower than
69% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ATEC: 2.17 )
Ranked among companies with meaningful Current Ratio only.
ATEC' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.88 Max: 3.39
Current: 2.17
0.75
3.39
Quick Ratio 1.27
ATEC's Quick Ratio is ranked lower than
72% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. ATEC: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
ATEC' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.13 Max: 2.53
Current: 1.27
0.4
2.53
Days Inventory 260.72
ATEC's Days Inventory is ranked lower than
89% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. ATEC: 260.72 )
Ranked among companies with meaningful Days Inventory only.
ATEC' s Days Inventory Range Over the Past 10 Years
Min: 205.28  Med: 244.21 Max: 339.71
Current: 260.72
205.28
339.71
Days Sales Outstanding 41.31
ATEC's Days Sales Outstanding is ranked higher than
77% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. ATEC: 41.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATEC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.31  Med: 74.37 Max: 95.46
Current: 41.31
41.31
95.46
Days Payable 30.75
ATEC's Days Payable is ranked higher than
55% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. ATEC: 30.75 )
Ranked among companies with meaningful Days Payable only.
ATEC' s Days Payable Range Over the Past 10 Years
Min: 30.75  Med: 80.41 Max: 117.79
Current: 30.75
30.75
117.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
ATEC's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. ATEC: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATEC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -69.9  Med: -22.5 Max: -0.4
Current: -3.1
-69.9
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.15
ATEC's Price-to-Median-PS-Value is ranked higher than
97% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ATEC: 0.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATEC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.01 Max: 2.67
Current: 0.15
0.14
2.67
Earnings Yield (Greenblatt) % -68.62
ATEC's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. ATEC: -68.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATEC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -68.82  Med: 2.7 Max: 4.6
Current: -68.62
-68.82
4.6

More Statistics

Revenue (TTM) (Mil) $125.6
EPS (TTM) $ -3.29
Beta1.89
Short Percentage of Float18.37%
52-Week Range $1.93 - 9.65
Shares Outstanding (Mil)10.86

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.01
EPS without NRI ($) 0.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATEC

Headlines

Articles On GuruFocus.com
Alphatec Holdings to Report First Quarter 2017 Financial Results on May 11, 2017 May 08 2017 
Alphatec Spine Launches Battalion™ Lateral System with Squadron™ Retractor to support Mini Apr 07 2017 
Alphatec Spine Adds Experienced Spine Executives to Sales Leadership Team Apr 05 2017 
Alphatec Completes its Senior Leadership Team with Appointment of Brian Snider, Executive Vice Presi Mar 24 2017 
Alphatec Holdings Announces $18.9 Million Private Placement Mar 23 2017 
Alphatec Spine Appoints Jeffrey G. Black as Chief Financial Officer Mar 06 2017 
Weekly CEO Buys Highlight: TDY, GDI, ATEC, PBCT, SPAR Mar 17 2012 
Alphatec Holdings Inc. Reports Operating Results (10-Q) Nov 08 2010 
Alphatec Holdings Inc. (ATEC) CEO Dirk Kuyper buys 23,000 Shares Aug 27 2010 
Alphatec Holdings Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Edited Transcript of ATEC earnings conference call or presentation 11-May-17 8:30pm GMT May 19 2017
Alphatec reports 1Q loss May 11 2017
Alphatec Holdings Reports First Quarter 2017 Financial Results May 11 2017
Investor Network: Alphatec Holdings, Inc. to Host Earnings Call May 11 2017
Alphatec Holdings to Report First Quarter 2017 Financial Results on May 11, 2017 May 08 2017
ETFs with exposure to Alphatec Holdings, Inc. : May 3, 2017 May 03 2017
ETFs with exposure to Alphatec Holdings, Inc. : April 10, 2017 Apr 10 2017
Alphatec Holdings, Inc. :ATEC-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017 Apr 07 2017
Alphatec Spine Launches Battalion™ Lateral System with Squadron™ Retractor to support Minimally... Apr 07 2017
Alphatec Spine Adds Experienced Spine Executives to Sales Leadership Team Apr 05 2017
Alphatec Completes its Senior Leadership Team with Appointment of Brian Snider, Executive Vice... Mar 24 2017
Alphatec Holdings Announces $18.9 Million Private Placement Mar 23 2017
Alphatec Holdings Announces Fourth Quarter and Full Year 2016 Financial Results Mar 15 2017
Alphatec Spine Appoints Jeffrey G. Black as Chief Financial Officer Mar 06 2017
Alphatec’s Arsenal™ Deformity Adolescent Scoliosis (AIS) System Launched in Limited Markets in... Feb 28 2017
ETFs with exposure to Alphatec Holdings, Inc. : January 20, 2017 Jan 20 2017
Alphatec Slides on Management Changes Dec 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}